drugset
drugset / Trial / NCT01067066

A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma

NCT01067066 ↗

Phase 1 Terminated 21 enrolled M.D. Anderson Cancer Center Cortice Biosciences, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The goal of the Phase I portion of this study is to find the highest tolerable dose of TPI 287 that can be given in combination with Temodar (temozolomide) to patients with metastatic melanoma. The goal of the Phase II portion of this study is to learn if TPI 287, given in combination with temozolomide, can control metastatic melanoma. The safety of this combination will also be studied. NOTE: Study stopped before progressing to Phase II portion.

Timeline

Start
2010-02-03
Primary completion
2016-07-06
Completion
2016-07-06

Drugs

EvaluationDrugModalityDoseRoute
Subject TPI 287 Small molecule 90 mg/m2 Intravenous
Subject Temozolomide Small molecule 85 mg/m2 Oral

Indications

melanoma